People receive plasma transfusions when their blood can’t clot properly and they’re bleeding or at serious risk of bleeding. Plasma is the liquid portion of blood, and it carries the proteins responsible for forming clots. When those proteins are missing or depleted, whether from trauma, liver disease, or a genetic condition, a plasma transfusion delivers a concentrated supply of what the body is lacking.
What Plasma Actually Does in Your Body
About 55% of your blood is plasma, a pale yellow fluid that carries red blood cells, white blood cells, and platelets through your circulatory system. But plasma also contains dozens of clotting proteins (called coagulation factors) that work together in a chain reaction to stop bleeding. When you cut yourself, these proteins activate one after another until they form a mesh of fibrin that seals the wound.
When someone receives a plasma transfusion, they’re getting those clotting proteins directly into their bloodstream. A dose based on body weight can raise clotting factor levels by 10 to 15%. The plasma must be blood-type compatible with the recipient and is given through an IV, typically over about an hour.
Major Trauma and Massive Blood Loss
The most urgent reason people receive plasma is severe trauma. When someone loses a large volume of blood from a car accident, gunshot wound, or major surgery, their clotting system can fail. The body runs out of clotting proteins faster than it can make them, and the remaining blood becomes too diluted to form clots effectively.
In these situations, trauma teams follow what’s called a massive transfusion protocol. The current approach uses a balanced ratio of red blood cells, plasma, and platelets (roughly 1:1:1) to mimic whole blood. This strategy has replaced older methods that relied heavily on saline and other clear fluids, which diluted the blood further and led to worse outcomes including prolonged time on a ventilator, tissue swelling, and longer hospital stays. Severe postpartum hemorrhage, one of the leading causes of maternal death worldwide, uses the same balanced approach.
Liver Disease and Impaired Clotting
Your liver manufactures most of your clotting proteins. When the liver is severely damaged, as in advanced cirrhosis or acute liver failure, it can no longer produce enough of these proteins, and blood tests show dangerously prolonged clotting times.
Doctors measure clotting ability with a blood test called the INR. A normal INR is around 1.0. When it climbs above 1.5 to 2.0, clinicians consider plasma transfusion, though the threshold depends on whether the patient is actively bleeding or about to undergo a procedure. Notably, major liver disease guidelines from the U.S. and Europe recommend against giving plasma just to correct an abnormal number on a lab test. The consensus is that plasma should be reserved for patients with cirrhosis who are actively bleeding or facing a procedure with significant bleeding risk, not given routinely before low-risk procedures like draining abdominal fluid.
Disseminated Intravascular Coagulation (DIC)
DIC is a dangerous condition where the clotting system goes haywire. The body forms tiny clots throughout the bloodstream, using up clotting proteins and platelets so rapidly that uncontrolled bleeding follows. It doesn’t happen on its own; it’s triggered by severe infections, certain cancers, major trauma, or complications of pregnancy.
Plasma transfusion is a key part of managing DIC because it replenishes the clotting factors the body has burned through. In pregnancy-related DIC, plasma has proven especially important for patients whose fibrinogen (one of the most critical clotting proteins) has dropped to dangerously low levels. Treating the underlying cause of DIC is essential, but plasma buys time by restoring the blood’s ability to clot.
Blood Thinner Reversal
Patients on warfarin (a common blood-thinning medication) sometimes need their clotting ability restored quickly, particularly if they develop bleeding in the brain. A systematic review supports plasma use specifically for warfarin-related bleeding inside the skull, where every minute of continued bleeding can cause permanent damage. In these emergencies, plasma provides the clotting factors that warfarin suppresses.
Rare Genetic Bleeding Disorders
Some people are born without the ability to produce specific clotting proteins. For several of these conditions, pharmaceutical companies have developed concentrated versions of the missing protein. But for rarer deficiencies, like factor V deficiency, no commercial concentrate exists. Platelets and other blood products contain only minimal amounts of factor V, making plasma the only effective treatment for moderate to severe cases. These patients may need plasma transfusions whenever they have surgery, dental work, or a bleeding episode.
Plasma Exchange for Autoimmune Conditions
Plasma isn’t always given to add something to the blood. Sometimes it’s used to replace something harmful. In a procedure called therapeutic plasma exchange, a machine removes the patient’s plasma, filters out the disease-causing substances, and returns the blood cells along with donor plasma or a protein solution.
The clearest example is thrombotic thrombocytopenic purpura (TTP), a rare but life-threatening condition where an abnormal immune response causes widespread tiny blood clots. Plasma exchange is the recommended first-line treatment. It removes the harmful antibodies driving the disease while simultaneously replacing a critical enzyme the patient is missing. Without plasma exchange, TTP is fatal in most cases.
Risks of Receiving Plasma
Plasma transfusion is not risk-free, which is why guidelines emphasize giving it only when there’s a clear clinical need. The two most significant complications involve the lungs.
Transfusion-associated circulatory overload (TACO) occurs when the volume of fluid overwhelms the heart’s ability to pump it. It causes fluid to back up into the lungs, making breathing difficult. TACO affects roughly 1% of transfused patients, with higher rates in people who are critically ill or receiving large volumes. Transfusion-related acute lung injury (TRALI), a more severe immune reaction that inflames the lungs, was historically seen in about 0.1% of transfused patients. After blood banks began screening donors to reduce triggering antibodies, prospective studies found the rate dropped dramatically to less than 0.001%.
Allergic reactions, fever, and rarely transmitted infections are also possible. These risks are one reason clinicians increasingly follow evidence-based guidelines that discourage plasma transfusion when the benefit is uncertain, such as giving it solely to normalize a lab value in someone who isn’t bleeding.
Fresh Frozen vs. Thawed Plasma
Plasma is frozen within hours of donation to preserve its clotting proteins, earning the name “fresh frozen plasma.” When needed, it must be thawed before use, which takes about 30 minutes. Some hospitals keep pre-thawed plasma on hand for emergencies. Thawed plasma contains nearly all the same clotting factors as fresh frozen, with modestly lower levels of two specific factors (V and VIII). It remains usable for up to five days after thawing, which reduces waste and ensures faster availability in trauma situations where minutes matter.